Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...

For patients who have progressed on endocrine therapy, consistent monitoring of blood counts and biomarker testing informs ...

Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even ...

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

Panelists highlight that being a care partner is one of the most challenging roles, requiring emotional resilience, ...

CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...

Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according ...

Volumetric PET biomarkers may help predict risk of toxicity from CAR T-cell therapy in patients with large B-cell lymphoma, ...

In TP53 wild-type advanced or recurrent endometrial cancer, selinexor improved multiple time-to-event outcomes vs placebo.

Planning for adverse effects early on helps patients prepare for what lies ahead, says Michelle Kirschner, MSN, RN, ACNP, ...